Pfizer CEO: We can't pursue COVID-19 vaccine approval until late November

Pfizer won't seek Covid-19 vaccine approval before mid-November

Pfizer to seek vaccine approval in November

If there's a sufficient supply, ME says it would have the capacity to vaccinate 80 percent of the state's 1.3 million people within 12 weeks of when a vaccine becomes available.

Pfizer Inc said on Friday it could file in late November for USA authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.

Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.

Pfizer and BioNTech's vaccine candidate, BNT162b2, is now being evaluated in a global Phase 3 study ongoing at more than 120 clinical sites worldwide including the United States, Brazil, South Africa and Argentina. According to Healthline, a task force organized by the National Academy of Sciences, Engineering and Medicine, also released its recommendations on which individuals should get vaccinated first when a COVID-19 vaccine is available. This disclosure did not appear to affect the development of the trials and the forecasts of both companies to obtain their vaccine against COVID-19 before the end of the year are maintained.

It has forecast that 35 million to 45 million doses of vaccines will be available in the United States by the end of this year from the first two companies to receive authorization.

"Viral vector" varieties use other forms of live virus to deliver DNA into human cells, triggering an immune response.

To date, only the result of Phase 1 and 2 trials have been published in peer-reviewed medical journals.

"Here in Maine, we are planning for the arrival of a COVID-19 vaccine, whenever that might be", Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention, said during his Thursday news conference. Trials of two candidate vaccines - made by Johnson & Johnson and Eli Lilly - were "paused" recently over safety concerns.

Companies backed by their governments in China, Russia and the United States are racing to be the first across the finish line.

But experts warn that even when vaccines are approved, it will take many months until they are widely available.

But there were few takers outside of Russian Federation, and experts dismissed the announcement as premature.

And on Friday, Pfizer said its vaccine wouldn't be ready until mid-November. Pfizer Inc has reportedly said that it may file for emergency-use authorisation of the coronavirus vaccine by late November, provided it gets positive efficacy and safety data from ongoing Phase 3 clinical trials.

Maine's system for distributing an eventual COVID-19 vaccine will prioritize racial equity and protecting health care workers and the elderly, according to a plan the state submitted to the federal government on Friday.

But even that pressing need can not overcome the rules.

Women's Marches Being Held In Washington, D.C., Cities Nationwide
York Region added to Ontario COVID-19 hotspots